Color Doppler ultrasonography and serum CA 125 in the differentiation of benign and malignant ovarian tumors

• Published in: Journal of clinical ultrasound Vol. 22; no. 8; p. 491
• Main Authors: Chou, C Y, Chang, C H, Yao, B L, Kuo, H C
• Format: Journal Article
• Language: English
• Published: United States 01.10.1994
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; CA-125 Antigen - blood; Child; Diagnosis, Differential; Female; Humans; Middle Aged; Ovarian Neoplasms - blood; Ovarian Neoplasms - blood supply; Ovarian Neoplasms - diagnostic imaging; Predictive Value of Tests; Radioimmunoassay; Regional Blood Flow; Sensitivity and Specificity; Ultrasonography, Doppler, Color
• ISSN: 0091-2751
• DOI: 10.1002/jcu.1870220806

Color Doppler ultrasonography and serum CA 125 were used to evaluate 114 adnexal tumors prior to surgery. Six patients were excluded from this study because of ovarian cancer, borderline ovarian malignancy, and tubal gestation. A total of 108 patients were eligible: 83 patients with benign and 25 patients with malignant ovarian tumors. Resistance index (RI) was used to determine the peripheral resistance of intratumoral vessels. The cutoff point for the RI was defined as 0.5. The blood flow was considered to be normal when the RI was greater than 0.5 and abnormal when it was less than 0.5. The blood flow was detected in 100% of malignant tumors and 59% of benign tumors. The initial cutoff value for CA 125 was 35 U/mL. Sensitivity, specificity, positive predictive value, and negative predictive value were compared in terms of RI, serum CA 125, and a combination of the two. Our conclusion is that the combination of RI and CA 125 gives a sensitivity of 100% and negative predictive value of 100%. If the cutoff point of CA 125 was raised from 35 to 65 U/mL, then a specificity of 100% and positive predictive value of 100% were also attained with the use of RI and CA 125 without changes in sensitivity or negative predictive value. We conclude that the combination of color Doppler ultrasonography and serum CA 125 is an effective method to differentiate benign from malignant ovarian tumors.